Supplemental Figure Legends and Figures 1-7 from The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

Supplemental Figure Legends; Supplemental Figure 1. JQ1 induces G1 accumulation without enhancing the sub-G1 population in sensitive sarcoma cell lines. Cells were exposed for 24 Hr to 500 nM JQ1; Supplemental Figure 2. Quantitation of immunoblots from Figure 1B, and 1C. MYC proteins are normalized against GAPDH; Supplemental Figure 3. JQ1 inhibits angiogenesis in rhabdomyosarcoma xenografts. CD34-positive staining (left panels; magnification 417X) and quantitation of IHC (right panels) for Rh10, and Rh28 rhabdomyosarcoma xenografts after 7 or 14 daily treatments with JQ1 or no treatment (controls); Supplemental Figure 4. JQ1 inhibits angiogenesis in Ewing sarcoma xenografts. CD34- positive staining (left panels; magnification 417X) and quantitation of IHC (right panels) for EW-5 and EW-8 Ewing sarcoma xenografts after 7 or 14 daily treatments with JQ1 or no treatment (controls); Supplemental Figure 5. Summary of JQ1 induced changes in angiogenic factors as determined by angiogenesis arrays in xenografts harvested from mice after 14 days treatment with JQ1, or HUVECs in vitro (0.5 μM 24 hr); Supplemental Figure 6. JQ1 does not inhibit the proliferative compartment in rhabdomyosarcoma xenografts. Ki67-positive staining (left panels; magnification 417X) was quantitated for Rh10, and Rh28 xenografts (right panels; magnification 417X) after 7 or 14 daily treatments with JQ1 or no treatment (controls); Supplemental Figure 7. JQ1 does not inhibit the proliferative compartment in Ewing sarcoma xenografts. Ki67-positive staining (left panels; magnification 417X) was quantitated for EW-5 and EW-8 xenografts (right panels; magnification 417X) after 7 or 14 daily treatments with JQ1 or no treatment (controls).</p